Previously, the inhibition of CYP17A1 or cyclooxygenase-2 (COX-2) has been revealed to sensitize GBM cells to TMZ treatment in vitro and in vivo [44, 48]. This evidence concerns the gene CYP17A1 and glioblastoma.